Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.
Arce Vargas F, Furness AJS, Solomon I, Joshi K, Mekkaoui L, Lesko MH, Miranda Rota E, Dahan R, Georgiou A, Sledzinska A, Ben Aissa A, Franz D, Werner Sunderland M, Wong YNS, Henry JY, O'Brien T, Nicol D, Challacombe B, Beers SA; Melanoma TRACERx Consortium; Renal TRACERx Consortium; Lung TRACERx Consortium; Turajlic S, Gore M, Larkin J, Swanton C, Chester KA, Pule M, Ravetch JV, Marafioti T, Peggs KS, Quezada SA. Arce Vargas F, et al. Among authors: chester ka. Immunity. 2017 Apr 18;46(4):577-586. doi: 10.1016/j.immuni.2017.03.013. Epub 2017 Apr 11. Immunity. 2017. PMID: 28410988 Free PMC article.
Antibody-drug conjugates - a perfect synergy.
Adair JR, Howard PW, Hartley JA, Williams DG, Chester KA. Adair JR, et al. Among authors: chester ka. Expert Opin Biol Ther. 2012 Sep;12(9):1191-206. doi: 10.1517/14712598.2012.693473. Epub 2012 Jun 1. Expert Opin Biol Ther. 2012. PMID: 22650648 Review.
The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.
Thistlethwaite FC, Gilham DE, Guest RD, Rothwell DG, Pillai M, Burt DJ, Byatte AJ, Kirillova N, Valle JW, Sharma SK, Chester KA, Westwood NB, Halford SER, Nabarro S, Wan S, Austin E, Hawkins RE. Thistlethwaite FC, et al. Among authors: chester ka. Cancer Immunol Immunother. 2017 Nov;66(11):1425-1436. doi: 10.1007/s00262-017-2034-7. Epub 2017 Jun 28. Cancer Immunol Immunother. 2017. PMID: 28660319 Free PMC article. Clinical Trial.
A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug.
Mayer A, Francis RJ, Sharma SK, Tolner B, Springer CJ, Martin J, Boxer GM, Bell J, Green AJ, Hartley JA, Cruickshank C, Wren J, Chester KA, Begent RH. Mayer A, et al. Among authors: chester ka. Clin Cancer Res. 2006 Nov 1;12(21):6509-16. doi: 10.1158/1078-0432.CCR-06-0769. Clin Cancer Res. 2006. PMID: 17085666 Clinical Trial.
Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer.
Chester KA, Mayer A, Bhatia J, Robson L, Spencer DI, Cooke SP, Flynn AA, Sharma SK, Boxer G, Pedley RB, Begent RH. Chester KA, et al. Cancer Chemother Pharmacol. 2000;46 Suppl:S8-12. doi: 10.1007/pl00014055. Cancer Chemother Pharmacol. 2000. PMID: 10950140 Review.
Clinical issues in antibody design.
Chester KA, Hawkins RE. Chester KA, et al. Trends Biotechnol. 1995 Aug;13(8):294-300. doi: 10.1016/S0167-7799(00)88968-4. Trends Biotechnol. 1995. PMID: 7662305 Review.
106 results